Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 10Lung Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Neoplasms 5Head and Neck Neoplasms 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Squamous Cell 5Neoplasm Metastasis 4Colorectal Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma 3Esophageal Neoplasms 3Urinary Bladder Neoplasms 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Hematologic Neoplasms 2Glioma 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unilateral HER2 Positive Breast Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Cancers of the Head and Neck 1Solid Tumors 1

Interventions

Gemcitabine 15Cisplatin 9Paclitaxel 6Nivolumab 5Fluorouracil 4Carboplatin 4atezolizumab 3Sunitinib 3Specimen Handling 3Radiotherapy 3Doxorubicin 3pegfilgrastim 2eribulin 2cabozantinib 2avelumab 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Ifosfamide 2Docetaxel 2CTLA-4 Antigen 2Biopsy 2vinflunine 1vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1rubitecan 1romidepsin 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urethral Neoplasms × Afatinib × Clear all
NCT02122172 2025-04-25

Afatinib in Advanced Refractory Urothelial Cancer

University of Chicago

Phase 2 Terminated
32 enrolled 14 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡